

## DAFTAR PUSTAKA

- Alave, J., Paz, J., Gonzalez, E., Campos, M., Rodriguez, M., Williq, J., Echevarria, J. (2013). *Risk Factors Associated with Virologic Failure in HIV- Infected Patients Receiving Antiretroviral Therapy at A Public Hospital in Peru*. *Rev Chilena Infectol*. 2013 Feb; 30(1): 42–48
- Alferd, SE. (1991). *Viral Infections of Humans, Epidemiology and Control* (3rd ed.). Sydney : Springer.
- Ali, A.M.G., Dawson, S-J., Blows, F.M., Provenzano, E., Ellis, I.O., Baglietto, L., Huntsman, D., *et al.* (2011). *Comparison of Methods for Handling Missing Data on Immunohistochemical Markers in Survival Analysis of Breast Cancer*. *British Journal of Cancer* (2011) 104, 693 – 699
- Ambler, G., Omar, R.Z., Royston, P. (2007). *A Comparison of Imputation Techniques for Handling Missing Predictor Values in A Risk Model with A Binary Outcome*. *Stat Methods Med Res* 16: 277 – 298
- Blatnerr, WA. (1991). HIV Epidemiology: Past, Present, and Future. *FASEB J*, Jul; 5 (10):2340-8.
- Boettiger, D.C., Kerr, S., Ditangco, R., Merati, T.P., Pham, T.T.T., Chaiwarith, R. Kiertiburanakul, S., *et al.* (2014). Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. *PLoS ONE* 9(9): e106525
- Brahma, D., Marak, M., Wahlang, J. (2012). *Rational Use of Drugs and Irrational Drug Combinations*. *The Internet Journal of Pharmacology*, Volume 10 Number 1.
- Carr, A., Cooper, DA: 1995. *Pathogenesis and Management of HIV-associated Drug Hypersensitivity*. *AIDS Clin Rev* 1995; 96: 65-97
- [Carey, D.](#), [Puls, R.](#), [Amin, J.](#), [Losso, M.](#), [Phanupak, P.](#), [Foulkes, S.](#), [Mohapi, L.](#), *et al.* (2015). *Efficacy and Safety of Efavirenz 400 mg Daily Versus 600 mg Daily: 96-Week Data from the Randomised, Double-Blind, Placebo-Controlled, Non-Inferiority ENCORE1 Study*. [Lancet Infect Dis](#). 2015 Jul;15(7):793-802
- CDC. (1993). Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Diakses dari <http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm> pada tanggal 24 Agustus 2014
- CDC. (2014). *Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis*. Diakses dari [http://www.cdc.gov/tb/publications/guidelines/tb\\_hiv\\_drugs/](http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/) pada tanggal 10 Januari 2016
- CDC. (2015). *Opportunistic Infections*. Diakses dari <http://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html> pada tanggal 20 Maret 2016
- Chaponda, M., Khoo, S.H., Oosterhout, J.V., Kumwenda, J., Zijlstra, Lalloo, D.S.W., Heyderman, R., *et al.* (2009). *Nevirapine Hypersensitivity in Malawi: A Prospective Cohort Study*. Dipresentasikan pada 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009. Diakses dari <http://www.hiv-druginteractions.org/data/abstract/AbstractID200.pdf> pada 20 September, 2014.
- Chaponda, M., Prmohamed, M. (2011). Hypersensitivity Reactions to HIV Therapy. *British Journal of Clinical Pharmacology*;71:5:659-671
- Chu, K.M., Boulle, A.M., Ford, N., Goemaere, E., Asselman, V., Cutsem, G.V. (2010) *Nevirapine-Associated Early Hepatotoxicity: Incidence, Risk Factors, and Associated Mortality in a Primary Care ART Programme in South Africa*. *PLoS ONE* 5(2): e9183



- Cozzi-Lepri, A., Philips, A.N., Monforte, A., Nicollo, P., Orani, A.O., Petrosillo, N., Leoncini, F., *et al.* (2002). *Virologic and Immunologic Response to Regimens Containing Nevirapine or Efavirenz in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study*. [The Journal of Infectious Diseases](#) Volume 185, Issue 8.
- d'Arminio, M.A., Lepri, A.C., Rezza, G., Pezzotti, P., Antinori, A. (2000) *Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients*. *AIDS* 14:499–507.
- Dahlan, M.S. (2009). *Analisis Survival: Dasar-Dasar Teori dan Aplikasi*. Jakarta: Epidemiologi Indonesia
- De, D., Sarkar, R.N., Phaujdar, S., Bhattacharyya, K., Pal, H.K. (2011). *Incidence and Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-TB Coinfected Patients*. *Braz J Infect Dis* 2011; 15(6):553-559
- Departemen Kesehatan RI. (2004). *Modul Pelatihan Konseling dan Tes Sukarela HIV*. Jakarta : Ditjen Pelayanan Medik & Ditjen PP & PL.
- Departemen Kesehatan RI. (2005). *Modul Pelatihan Dasar Perawatan, Dukungan dan Pengobatan ODHA*. Jakarta : Ditjen Pelayanan Medik & Ditjen PP & PL.
- Departemen Kesehatan DIY. (2014). *Profil Kesehatan DIY 2014*. DIY : Dinas Kesehatan DIY.
- Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. *Clin Infect Dis*. 2004;38(Suppl 2):S80–9
- Dinas Kesehatan DIY. (2015). *Laporan Program Penanggulangan HIV-AIDS*. DIY : Dinas Kesehatan
- Dong, Y., Peng, C.Y.J. (2013). *Principled Missing Data Methods for Researchers*. Springerplus. 2013; 2: 222
- Dunn, S. (2002). *Survival Curves: Accrual and The Kaplan-Meier Estimate*. Diakses dari [http://cancerguide.org/scurve\\_km.html](http://cancerguide.org/scurve_km.html) pada tanggal 5 Januari 2016
- Dwiyana, F.R., Rowawi, R., Lestari, M., Alisjahbana, B., Van der Ven, A.J.A.M., Djajakusumah, T.S. (2009). *Skin Disorders in HIV-infected Patients from West Java*. *Acta Med Indones-Indones J Intern Med* : Vol 41. Supplement 1. July 2009.
- Enders, C.K. (2003). *Using the Expectation Maximization Algorithm to Estimate Coefficient Alpha for Scales With Item-Level Missing Data*. *Psychol Meth*. 2003; 8(3): 322–337. doi: 10.1037/1082-989X.8.3.322
- Fitriawan, A.S. (2012). *Faktor-Faktor yang Mempengaruhi Kepatuhan Menjalankan Antiretroviral Therapy (ART) pada Pasien HIV/AIDS yang Melakukan Rawat Jalan di RSUP Dr. Sardjito Yogyakarta*. *Skripsi*. Yogyakarta : Universitas Gadjah Mada.
- Fellay, J., Boubaker, K., Ledergerber, B., Bernasconi, E., Furrer, H. (2001) *Prevalence of Adverse Events Associated with Potent Antiretroviral Treatment : Swiss HIV Cohort Study*. *Lancet* 358:1322–1327.
- Ferdinand, W.N.M.W., Kesselring, A.M., Gras, L., Richter, C., Van der Ende, M.E., Brinkman, K., Lange, J.M.A., *et al.* (2008). *Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience, Compared with Treatment Naïve Patients: The ATHENA Cohort Study*. *Clinical Infectious Diseases* 2008; 46:933–40
- Firriolo, F.J., Miller, C.S., Rhodus, N.L. (2007). *Medical Management and Pharmacology Update*. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*; Vol 104: No.4



UNIVERSITAS  
GADJAH MADA

**Faktor-Faktor Yang Berhubungan Dengan Penggantian Nevirapine Pada Pasien HIV-AIDS Naive Di RSUP Dr. Sardjito**

NUR AINI KUSMAYANTI, Prof. dr. Hari Kusnanto, DrPH; dr. Yanri Wijayanti S, SpPD, PhD

Universitas Gadjah Mada, 2016 | Diunduh dari <http://etd.repository.ugm.ac.id/>

- Griensven, J.V., Zachariah, R., Rasschaert, F., Mugabo, J., Atte, E.F., Reid, T. (2010). *Stavudine- and Nevirapine-Related Drug Toxicity while on Generic fixed-Dose Antiretroviral Treatment: Incidence, Timing and Risk Factors in A Three-Year Cohort in Kigali, Rwanda*. Transactions of the Royal Society of Tropical Medicine and Hygiene 104 (2010) 148–153
- Hoffman, C., Rockstroh, J.K., Kamps, B.S. (2007). *HIV Medicine 2007*. Hamburg : Flying Publisher
- Katzung, B.G. 2004. *Basics & Clinical Pharmacology*. 9<sup>th</sup> ed. Singapore : McGraw-Hill
- Kawalec, P., Kryst, J., Mikrut, A., Pilc, A. (2013). *Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials*. PLoS ONE 8(10): e76587. doi:10.1371/journal.pone.0076587
- Kementrian Kesehatan RI. (2011). *Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa*. Jakarta : Kementrian Kesehatan RI.
- Kementrian Kesehatan RI. (2012). *Pedoman Pencegahan Penularan HIV dari Ibu ke Anak* (2nd ed). Jakarta : Kementrian Kesehatan RI.
- Kementrian Kesehatan RI. (2014). *Laporan Perkembangan Situasi HIV dan AIDS di Indonesia Tahun 2014*. Jakarta : Kementrian Kesehatan RI.
- Kementrian Kesehatan RI. (2014). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 tentang Pedoman Pengobatan Antiretroviral*. Jakarta : Kementrian Kesehatan RI
- Kenneth, G.C., John, W.W., Laurence, S., James, W.B., Harold, W., Jaffe, R.L.B. (1993). *Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults*. Center for Disease Control and Prevention. Diakses dari <http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm> pada September, 2014.
- Kim, J.O., Curry, J. (1977). *The Treatment of Missing Data in Multivariate Analysis*. Sociol Methods Res 6: 215 – 241
- Kirk, J.B., Goetz, M.B. (2009). *Human Immunodeficiency Virus in an Aging Population, A Complication of Success*. Journal of the American Geriatrics Society, November 2009; **57, (11)**: 2129–2138.
- Klat, E.C. (2014). *Pathology of AIDS Version 25*. Mercer University School of Medicine Savannah
- Knobel, H., Guelar, A., Montero, M., Carmona, A., Luque, S., Berenguer, N., Gonzalez, A. (2008). *Risk of Side Effects Associated with The Use of Nevirapine in Treatment-naïve Patients, with Respect to Gender and CD4 Cell Count*. HIV Medicine (2008), 9, 14–18
- Law, W.P., Dore, G.J., Duncombe, C.J., Mahanontharit, A., Boyd, M.A., Ruxrungtham, K., Lange, J.M.A., *et al.* (2003). *Risk of Severe Hepatotoxicity Associated With Antiretroviral Therapy in the HIV-NAT Cohort, Thailand, 1996-2001*. Wolters Kluwer Lippincott William&Wilkins AIDS.2003;17(15)
- Little, R.J.A., Rubin, D.B. *Statistical Analysis with Missing Data 2*. New York: Wiley
- Luigia, E., Marzolini, C., Furrer, H., Ledergerber, Bruno., Cavassini, M., Hirschel, B., Vernazza, P., *et al.* (2010). *Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008*. ARCH INTERN MED/VOL 170 (NO. 1), JAN 11, 2010
- Lenhard, J.M., Croom, D.K., Weiel, J.E., Spaltenstein, A., Reynolds, D.J., Furfine, Eric, S. (2000). *Dietary Fat Alters HIV Protease Inhibitor–Induced Metabolic Changes in Mice*. J. Nutr. September 1, 2000 vol. 130 no. 9 2361-2366
- Maggiolo, F., Arici, C., Airoidi, M., Ripamonti, D., Quinzan, G., Gregis, G., Ravasio, V., *et al.* (2007). *Journal of Antimicrobial Chemotherapy* (2007) 59, 569–572



- Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. *Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine*. HIV Clin Trials. 2003;4:115–20
- Meriki, H.D., Tufon, K.A., Afegenwi, M.H., Nyindem, B.A., Anong, D.N. Cho-Ngwa, F., Nkuo-Akenji, F., *et al.* (2014). Immuno-Haematologic and Virologic Responses and Predictors of Virologic Failure in HIV-1 Infected Adults on First-Line Antiretroviral Therapy in Cameroon. *Infectious Diseases of Poverty* 2014, 3:5
- Meyboom, R.H.B., Lindquist, M., Egberts, A.C.G. (2000). *An ABC of Drug-Related Problems*. *Drug Safety* 2000;22:415-23
- NIAID (National Institute of Allergy and Infection). (2009). HIV-AIDS. Diakses dari <http://www.niaid.nih.gov/topics/hivaids/understanding/howhivcausesaids/pages/howhiv.aspx> pada Agustus 2014.
- Nursalam, Kurniawati, Ninuk, D. (2007). *Asuhan Keperawatan pada Pasien Terinfeksi HIV/AIDS* (1st ed). Jakarta : Salemba Medika.
- Padmapriyadarsini, C., Bhavani, P.K., Tang, A., Kumar, H., Narendran, G., Hannah, E., Ramesh, C., *et al.* (2013). *Early Changes in Hepatic Function among HIV-Tuberculosis Patients Treated with Nevirapine or Efavirenz along with Rifampin-Based Anti-Tuberculosis Therapy*. *International Journal of Infectious Diseases* 17 (2013) e1154–e1159
- Paton, N.I., Sangeetha, S., Earnest, A., Bellamy, R. (2006). The Impact of Malnutrition on Survival and the CD4 Count Response in HIV-Infected Patients Starting Antiretroviral Therapy. *British HIV Association HIV Medicine* (2006), 7, 323–330
- Phanuphak, N., Apornpong, T., Teeratakulpisarn, S., Chaithongwongwatthana, S., Taweepolcharoen, C. (2007). *Nevirapine-associated Toxicity in HIV- infected Thai Men and Women, Including Pregnant Women*. *HIV Med.* 8(6): 357-366.
- Philips, E.J., Mallal, S.A. (2012). *Pharmacogenetics of Drug Hypersensitivity*. *Pharmacogenomics*. 2010 July ; 11(7): 973–987
- Prinitha, P., Nathan F., Zara, S., Rashida, A., Ferrand. (2013). *Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis*. *Plos One* July 2013, Volume 8, Issue 7, e68995.
- [Puls, R.](#), [Amin, J.](#), [Losso, M.](#), [Phanuphak, P.](#), [Nwizu, C.](#), [Orrell, C.](#), [Young, B.](#), *et al.* (2014). Efficacy of 400 mg Efavirenz versus Standard 600 mg Dose in HIV-Infected, Antiretroviral-Naive Adults (ENCORE1): A Randomised, Double-Blind, Placebo-Controlled, Non-Inferiority Trial. [Lancet](#). 2014 Apr 26;383(9927):1474-82.
- Rich, J.T., Neely, J.G., Paniello, R.C., Voelker, C.C.J., Nussenbaum, B., Wang, E.W. (2010). *A Practical Guide To Understanding Kaplan-Meier Curves*. *Otolaryngol Head Neck Surg.* 2010 September ; 143(3): 331–336
- Sarfo, F.S., Sarfo, M.A., Norman, B., Phillips, R., Chadwick, D. (2014). *Incidence and Determinants of Nevirapine and Efavirenz Related Skin Rashes in West Africans: Nevirapine's Epitaph?*. *PLoS ONE* 9(4): e94854.
- Schafer, J.L. (1999). *Multiple Imputation: A Primer*. *Stat Methods Med Res* 8: 3–15
- Scheffer, J. (2002). *Dealing with Missing Data*. *Res. Lett. Inf. Math. Sci.* (2002) 3, 153-160
- Sharma, S.K., Soneja, M. (2011). *HIV & Immune Reconstitution Inflammatory Syndrome (IRIS)*. *Indian J Med Res.* 2011 Dec; 134(6): 866–877
- Shearer, K., Brennan, A.T., Maskew, M., Long, L., Berhanu, R., Sanne, I., Fox., M.P. (2014). *The Relation Between Efavirenz versus Nevirapine and Virologic Failure in Johannesburg, South Africa*. *Journal of the International AIDS Society* 2014, 17:19065
- Shubber, Z., Calmy, A., Andrieux-Meyer, I., Vitoria, M., Renaud-Thery, F., Shaffer, N., Hargreaves, S., Mills, E.J., and Ford, N. (2013). *Adverse Events Associated with Nevirapine and Efavirenz-Based first-Line Antiretroviral Therapy: A Systematic Review*

- and Meta-Analysis*. Wolters Kluwer Health | Lippincott Williams & Wilkins AIDS 2013, 27:1403–1412.
- Sicotte, M., Langlois, É.V., Aho, J., Ziegler, D., Zunzunegui, M.V. (2014). Association between Nutritional Status and The Immune Response in HIV + Patients under HAART: Protocol for a Systematic Review. *Biomed Central: Systematic Reviews Journal* 2014, 3 : 9
- Stata. (2016). [Supplemental notes to Applied Survival Analysis – Applied Survival Analysis](#). Diakses dari [http://www.ats.ucla.edu/stat/examples/asa/test\\_proportionality.htm](http://www.ats.ucla.edu/stat/examples/asa/test_proportionality.htm) pada tanggal 10 Januari 2016
- Stolley, K.S., Glass, E.J. (2009). HIV/AIDS. Diakses dari [www.ebooks.abc-clio.com](http://www.ebooks.abc-clio.com) pada tanggal 1 September 2014.
- Susan, J., Bersoff-Matcha., Powderly, W.G., Miller, W.C., Mundy, L.M., Aberg, J.A., Vander-Horst, C., *et al.* *Sex Differences in Nevirapine Rash*. *Clinical Infectious Diseases* 2001; 32:124–9
- Tabachnick, B.G., Fidell, L.S. (2012). *Using multivariate statistics*. 6. Needham Heights, MA: Allyn & Bacon
- Tadesse, K., Haile, F., Hiruy, N. (2014). *Predictors of Mortality among Patients Enrolled on Antiretroviral Therapy in Aksum Hospital, Northern Ethiopia: A Retrospective Cohort Study*. *PLoS ONE* 9 (1): e87392. doi:10.1371/journal.pone.0087392
- The COHERE Study Group. Response to Combination Antiretroviral Therapy: Variation by Age. *AIDS*, 2008. 22:1463 – 1473.
- Thong, B.Y-H., Tan, T-C. (2011). *Epidemiology and Risk Factors for Drug Allergy*. *British Journal of Clinical Pharmacology*;71:5:684-700
- Tseng, Y-T., Yang, C-J., Chang, S-Y., Lin, S-W., Tsai, M-S., Liu, W-C., Wu, P-Y., *et al.* (2014). *Incidence and Risk Factors of Skin Rashes and Hepatotoxicity in HIV-Infected Patients Receiving Nevirapine-Containing Combination Antiretroviral Therapy in Taiwan*. *International Journal of Infectious Diseases* 29 (2014) e12–e17
- US Department of Health and Human Services. (2014). What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient|Adult and Adolescent ARV Guidelines|AIDSinfo. Diakses dari: <http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/11/what-to-start> pada Agustus 2014.
- U.S. Department of Health and Human Services. 2014. What Is HIV AIDS? Diakses dari <http://aids.gov/hiv-aids-basics/hiv-aids-101/what-is-hiv-aids/> pada Agustus 2014.
- US Department of Health and Human Services. 2014. How Do You Get HIV or AIDS?. Diakses dari <http://www.aids.gov/hiv-aids-basics/hiv-aids-101/how-you-get-hiv-aids/> pada September, 2014
- University of California San Francisco. (2016). Database of Antiretroviral Drug Interactions. Diakses dari <http://arv.ucsf.edu/insite?page=ar-00-02> pada tanggal 20 Maret 2016
- Umapathy, S., Pawar, A., Bajpai, S., Pazare, A.R., Ghosh, K. (2011). HLA Involvement in Nevirapine-Induced Dermatological Reaction in Antiretroviral-Treated HIV-1 Patients. *J Pharmacol Pharmacother*. 2(2):114–115.
- UNAIDS. (2013). *Global Report : UNAIDS Report on The Global AIDS Epidemic 2013*. WHO Library Cataloguing-in-Publication Data.
- University of California San Francisco. (2012). Adverse Effects of Antiretroviral Drugs. Diakses dari <http://hivinsite.ucsf.edu/insite?page=ar-05-01> pada September 2014
- Van Der Ven, A.J., Koopmans, P.P., Vree, T.B., Vander, M.J.W. (1991). *Adverse Reactions to Cotrimoxazole in HIV Infection*. *Lancet* 1991;ii:431-433
- van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., *et al.* (2004) Comparison of First-Line Antiretroviral Therapy with Regimens Including



- Nevirapine, Efavirenz, or Both Drugs, Plus Stavudine and Lamivudine: A Randomised Open-Label Trial, The 2NN Study. *Lancet* 2004; 363:1253–1263.
- Villamor, E., Saathoff, Mugusi, F., Urassa, W., Matsumoto, K., Meydani, S.N., Bosch, R.J., *et al.* (2008). *A Trial of the Effect of Micronutrient Supplementation on Treatment Outcome, T Cell Counts, Morbidity, and Mortality in Adults with Pulmonary Tuberculosis. J Infect Dis.* 2008 June 1; 197(11): 1499–1505. doi:10.1086/587846
- Werner, P.J. (2007). *Drug Hypersensitivity*. Basel : Werner
- Wexler, B. (2008). *The Information Series on Current Topics HIV/AIDS*. Texas: Cengage Learning. Geneva: WHO
- WHO. (2002). *Scaling up Antiretroviral Therapy in Resource-Limited-Settings. Guideline for a Public Health Approach*. Geneva: WHO.
- WHO. (2005). *Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance. Marketing and Dissemination*, World Health Organization. Geneva: WHO
- WHO. (2006). *HIV/AIDS Programme Strengthening health services to fight : HIV/AIDS Antiretroviral Therapy for HIV Infection in Adults and Adolescents : Recommendations for A Public Health Approach 2006 Revision*. Geneva: WHO
- WHO. (2009). *Summary of Available Safety Data for Nevirapine, Stavudine, Zidovudine and Tenofovir*. Geneva : WHO
- WHO. (2010). *Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for A Public Health Approach -2010 rev. WHO Guidelines*. Geneva: WHO
- WHO. (2011). *Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Department of Nutrition for Health and Development (NHD) World Health Organization*. Geneva: WHO
- WHO. (2013). *Summary of New Recommendations, Consolidated ARV Guidelines, June 2013*. Diakses dari <http://www.who.int/hiv/pub/guidelines/arv2013/en/> pada tanggal 2 Februari 2016
- WHO. (2014). *Use of Antiretrovirals for Treatment and Prevention of HIV Infection*. Diakses dari [www.who.int](http://www.who.int) pada 20 Juni 2014.
- WHO. (2015). *Fact Sheet HIV Treats and Care : What's New In HIV Treatment*. Geneva : WHO
- Williams, R. (2015). *Scalar Measures of Fit: Pseudo R2 and Information Measures (AIC & BIC)*. Diakses dari <http://www3.nd.edu/~rwilliam/> pada tanggal 29 Desember 2015
- Zhang, C., Wang, W., Zhou, M., Han, Y., Xie, J., Qiu, Z., Guo, F., *et al.* (2013). *The Interaction of CD4 T-Cell Count and Nevirapine Hepatotoxicity in China: A Change in National Treatment Guidelines May Be Warranted. J Acquir Immune Defic Syndr* 2013;62:540–545